Daily Stock List
WhereverTV Broadcasting Corp. (TVTV)
Information Solutions Group and OtcWizard reported last week on WhereverTV Broadcasting Corp. (TVTV), and today we are highlighting the Company as "One to Watch" here at the QualityStocks Daily Newsletter.
Founded in 2006, WhereverTV Broadcasting Corp. offers a global showcase of sports, news and entertainment - broadcast live over the internet. The Company delivers an ever-expanding directory of the video and music channels that people desire. WhereverTV is the next generation subscription television service. They provide consumers with programming identical to existing cable and satellite providers. WhereverTV Broadcasting has their corporate headquarters in Pittsburgh, Pennsylvania.
The WhereverTV platform manages broadcast rights across geographies. This platform provides individual customer viewing experiences based on customer locations (geo-targeting) and content-rights management (subscriptions). WhereverTV Broadcasting distributes subscription services directly through their Website, wherever.tv. In addition, they distribute through connected television platforms, including Roku, Boxee and Google TV.
The Company delivers the same channels and events through an over the top (OTT) service platform. They deliver these channels and events to single-family, multi-family, high-rises and businesses across North America. Their platform downlinks, encodes and broadcasts linear television programming across the Public Internet to Connected Televisions, Blu-ray players, set top boxes, tablet PCs, laptops and smartphones.
The Company is benefiting from growing public demand for "over the top" television services and a heightened awareness of WhereverTV's Greek & Arabic cable television subscription services. Without a foundational U.S. offering yet available, subscription revenues in 2012 were close to $100,000. This represents an approximate 500 percent increase over 2011. Greek and Arabic in-language content subscriptions, in tandem with other in-language sales commissions, accounted for 100 percent of this revenue.
WhereverTV also signed several carriage agreements with U.S. cable networks. This will enable them to launch a U.S. cable offering this calendar year. WhereverTV Broadcasting believes that their advantages include their lower cost infrastructure and customer acquisition/service costs that will be passed onto consumers in the form of lower monthly charges, a strong content offering, and premier customer service.
Furthermore, WhereverTV has started development of the WhereverTV digital video recording (DVR) application. This application will eliminate the need to have a stand-alone recording device in the home. The Company expects to launch this service in early 2013. Moreover, the Company worked on assembling content in 2012. They require this content to launch their U.S. basic cable service. By the end of calendar 2012, they had obtained carriage agreements from over 50 U.S. television networks. They are getting close to their objective of 80 channels needed to launch the U.S. service offering. WhereverTV expects to secure the remaining channels and launch the service during this first quarter of 2013.
We have WhereverTV Broadcasting Corp. (TVTV) locked on our radar screens as "One to Watch" this week here at the QualityStocks Daily Newsletter.
WhereverTV Broadcasting Corp. (TVTV), closed Tuesday's trading session at $0.99, up 10.00%, on 10,668 volume with 17 trades. The average volume for the last 60 days is 1,212 and the stock's 52-week low/high is $0.66/$4.50.
MusclePharm Corp. (MSLP)
The Online Investor, Bull in Advantage, FeedBlitz, Greenbackers, Alternative Energy, WallstreetSurfers, SizzlingStockPicks, and Purely Penny Stocks reported earlier on MusclePharm Corp. (MSLP), and we are highlighting the Company as "One to Watch" this week here at the QualityStocks Daily Newsletter.
MusclePharm Corp. is a nutritional supplement company focusing on active lifestyles. As a healthy lifestyle corporation, they develop and manufacture nutritional supplements that address active lifestyles, including muscle building, weight loss and maintaining general fitness through a daily nutritional supplement regimen. Founded in 2008, MusclePharm has their headquarters in Denver, Colorado. The Company lists on the OTC Market's OTCQB.
MusclePharm formulates their products through a six-stage research process. The Company sells their products to consumers in more than 110 countries. The products are available in more than 10,500 U.S. retail outlets, including Dick's Sporting Goods, GNC, Vitamin Shoppe and Vitamin World. MusclePharm products also sell through more than 100 online channels worldwide, including bodybuilding.com, amazon.com and vitacost.com.
The Company began formulating their nutritional supplements in 2008 for consumption by active individuals, high performance athletes, as well as fitness enthusiasts. They launched their sales and marketing programs in late 2008 via their internal sales executives and staff, targeting specialty retail distributors. MusclePharm's core marketing strategy is to brand MusclePharm as the "must have" fitness brand for workout enthusiasts and elite athletes. The Company is looking to have recognition as the athlete's company, run by athletes, who create their products for other athletes - professional and otherwise.
One of the Company's strategies is to increase their product distribution and sales through increased market penetrations - domestically and internationally. Another of their strategies is to increase awareness of their products by increasing their marketing and branding opportunities through endorsements, sponsorships and brand extensions.
MusclePharm's broad spectrum of nutritional supplements includes Assault, Combat Powder, MusclePharm Musclegel, MusclePharm Shred Matrix, and Re-Con. These products consist of amino acids, herbs and proteins, tested by the Company's scientists for the overall health of athletes. MusclePharm developed these nutritional supplements to enhance the effects of workouts, to repair muscles, and to nourish the body for optimal physical fitness.
Yesterday, MusclePharm announced that they successfully completed two closings of a registered direct offering of their Series D Convertible Preferred Stock. The Frost Group, LLC was the lead investor in the offering increasing the position in the Company by approximately $1.4 million. Miami entrepreneur Dr. Phillip Frost heads The Frost Group.
At the closings, MusclePharm issued 511,625 shares of their Series D Convertible Preferred Stock in a registered direct placement of their shares at a per share price of $8.00. Each share of Series D Convertible Preferred Stock is convertible into two shares of common stock, subject to adjustment. The net proceeds to MusclePharm from the closings were approximately $3.5 million after deducting placement agent fees and offering expenses.
We have MusclePharm Corp. (MSLP) in our sightlines as "One to Watch" this week here at the QualityStocks Daily Newsletter.
MusclePharm Corp. (MSLP), closed Tuesday's trading session at $5.65, up 0.89%, on 196,481 volume with 213 trades. The average volume for the last 60 days is 5,109 and the stock's 52-week low/high is $3.333/$31.25.
Passport Potash, Inc. (PPRTF)
StreetWise Reports, StockHouse, Jason Bond, and PennyStockLive reported previously on Passport Potash, Inc. (PPRTF), and we report on the Company today, here at the QualityStocks Daily Newsletter.
Passport Potash, Inc. engages in the exploration and development of advanced potash properties. Their primary focus is on a previously explored potash property in Arizona. Passport Potash has acquired a strategic position in the Holbrook Basin with land holdings encompassing more than 121,000 acres. The Company has their corporate headquarters in Vancouver, British Columbia. Their shares trade on the OTCQX International and on the TSX Venture Exchange under the symbol PPI.V. The Company has one wholly owned subsidiary, PPI Holding Corp., an Arizona corporation.
In addition, Passport Potash has entered into a joint exploration agreement with the Hopi Indian Tribe to work toward developing more than 13,000 acres of contiguous privately held Hopi land. The Holbrook Basin project is seven miles east of Holbrook, Arizona. The project sits atop a large salt basin known as the Holbrook Salt Basin.
Passport is utilizing the historic records combined with their own drilling program and seismic testing to substantiate the potash grade and quantity on their properties. Thirty new holes have been drilled on the Company's holdings since 2009, as well as 100 line miles of seismic survey.
Passport previously announced the completion of the initial NI 43-101 compliant mineral resource estimate by ERCOSPLAN Ingenieurgesellschaft Geotechnik und Bergbau mbH (ERCOSPLAN) for the Company's Holbrook Basin property in Northern Arizona. Headquartered in Erfurt, Germany, ERCOSPLAN is a consulting and engineering firm, specializing in the potash and salt industry.
This initial resource estimate consists of 125.6 million tonnes of indicated mineralized material with an average KCl grade of 14.29 percent (equivalent to an Indicated Resource of 17.96 million tonnes of KCl) and 587.8 million tonnes of inferred mineralized material with an average KCl grade of 12.20 percent (equivalent to an Inferred Resource of 71.71 million tonnes of KCl). Currently, the estimated resources cover only approximately 40 percent of Passport Potash's current holdings.
On January 21, 2013, Passport Potash announced a non-brokered private placement of convertible debentures for up to $2.5 million at an interest rate of 15 percent. The principal amount of the debentures is convertible into common stock of the Company at the option of the subscriber, in whole or in part, at a price of US$0.19 per share for a period of one year from the date of closing. The private placement is subject to the approval and consent of the TSX Venture Exchange. Upon approval by the Exchange, the subscriber shall receive five warrants for each US$1.00 of principal amount tendered in the Offering, entitling the holder to acquire one share for each warrant at an exercise price of US$0.19 per share for a period of one year from the date of issuance.
Passport Potash, Inc. (PPRTF), closed Tuesday's trading session at $0.199, down 4.78%, on 241,225 volume with 29 trades. The average volume for the last 60 days is 140,634 and the stock's 52-week low/high is $0.16/$0.35.
Progressive Care, Inc. (RXMD)
We are reporting on Progressive Care, Inc. (RXMD), here at the QualityStocks Daily Newsletter.
Progressive Care, Inc. and their subsidiary PharmCo, LLC, a provider of prescription pharmaceuticals, specializing in anti-retroviral patient care, long-term care and durable medical equipment (DME), have operations that are currently focusing on the South Florida market. This market is where Management believes demographics are synergistic with their marketing efforts of anti-retroviral patient management and their DME product line. Progressive Care is based in Miami Gardens, Florida.
The Company's dedication is to improving the quality of life of special needs patients through increasing access to vital medication and equipment, raising awareness, and providing education and other services to local communities and long-term care institutions. Progressive Care's PharmCo subsidiary additionally provides long-term care solutions to skilled nursing facilities (SNFs), assisted living facilities (ALFs), retirement centers and communities, doctors' offices as well as clinics.
PharmCo is a fully accredited DME supplier. In November 2010, PharmCo was awarded a three-year contract to supply hospital beds, oxygen supplies, power wheelchairs, scooters, walkers, and other related equipment and accessories in South Florida. They carry an extensive inventory of equipment and accessories. Most special requests are honored with same day or next day delivery.
PharmCo offers sales and rentals. They offer home service and maintenance, defective product replacements, and free home installation and instruction. They provide long-term care institutions with on time, same day deliveries available twice a day with 24-hour emergency support. Additionally, they provide unit-dose packaging options tailored to a facility's requirements. PharmCo has extensive medication and DME inventory and they provide access to OTC medications, nutritional products and personal hygiene items. They also provide monthly pharmacy consultations and compliance updates and consultations.
Progressive Care is moving forward in their endeavors to grow the Company. This is by expanding their facility, adding new locations, acquiring operating pharmacies, and further developing their current business lines.
In November 2012, Progressive Care, and subsidiary PharmCo, announced that they signed two-year contracts with seven healthcare institutions located within the South Florida area to provide all necessary pharmacy services. With these agreements, PharmCo will become each facility's designated provider of pharmaceutical products and services.
PharmCo will be responsible for providing approved prescription and non-prescription drugs, intravenous products, respiratory supplies, enteral and parenteral nutritional products and other pharmaceutical supplies and services. These agreements commenced on September 30, 2012.
Progressive Care, Inc. (RXMD), closed Tuesday's trading session at $0.0897, down 10.12%, on 9,870 volume with 4 trades. The average volume for the last 60 days is 9,072 and the stock's 52-week low/high is $0.03/$0.55.
Cicero, Inc. (CICN)
OTCPicks reported previously on Cicero, Inc. (CICN), and we choose to highlight the Company today, here at the QualityStocks Daily Newsletter.
Cicero, Inc. provides solutions that enable business transformation of enterprise interactions across companies and government organizations. The Company is an international provider of Customer Experience Management (CEM) and integration technologies. The design of their products is to give businesses accurate information concerning performance and to reshape data to drive specific work and service outcomes. Cicero XM® technology allows business and Information Technology (IT) to "find" problems with applications and the use of them.
Cicero has their headquarters in Cary, North Carolina. Their shares trade on the OTC Bulletin Board. Founded in 1988, the Company formerly went by the name Level 8 Systems, Inc. They subsequently changed their name to Cicero, Inc. in January of 2007.
The Company's Cicero XM® technology delivers solutions through an inventive combination of desktop integration, automation, presentation and analytics capabilities. These are built to transform customer interaction into the most robust marketing and branding asset a business can own. Cicero software solutions feature ease of configuration and change control, eliminating up to 90 percent of the change control costs and time, providing the ability to deliver actionable intelligence by way of an efficient combination of telephony and interaction data, and delivering immediate benefits with a Return on Investment (ROI) in less than six months.
Cicero XM is a CEM solution for contact centers and the enterprise. It simplifies workflow, automates tasks, and automatically shares data between any applications from back office to desktop servicing solutions. Cicero XM is a non-invasive solution; it does not require taking away or hiding users' access to existing applications. It simplifies, extends, and automates processes using those applications while allowing new applications to undergo integration simply and quickly. Additionally, Cicero XM features tools to create a modular, customizable interface, scripting or user guidance, screen pops, new composite applications, and a powerful toolbar.
Last week, Cicero announced that a Fortune 500 Provider of insurance products and services with more than $115 Billion in assets signed an enterprise software license and services agreement to deliver an integrated Cicero XM Smart Desktop solution for their call centers. The Insurance Provider will be using Cicero's award-winning Cicero XM technology to implement a call center enhanced desktop with automated sign-on, application quick launch, automated search and navigation, consolidated views of key information and other features.
Cicero, Inc. (CICN), closed Tuesday's trading session at $0.08, up 33.33%, on 20,000 volume with 4 trades. The average volume for the last 60 days is 35,925 and the stock's 52-week low/high is $0.51/$0.10.
Neutra Corp. (NTRR)
OTC Stock Pick reported this month on Neutra Corp. (NTRR), Best Microcap Stock did previously, and we are reporting on the Company today, here at the QualityStocks Daily Newsletter.
Neutra Corp. is a healthy lifestyle company whose shares trade on the OTC Bulletin Board. The Company's dedication is to commercializing innovative, all-natural products to compete in the fast-growing wellness sector. Currently, Neutra is working to produce a complete family of products to address every component of a healthy lifestyle (including addiction recovery, weight loss and general wellness) through a daily nutrition regimen. Neutra is based in Tampa, Florida.
The Company will compete in the fast-growing wellness sector alongside Herbalife Ltd. (HLF), Vitamin Shoppe (VSI), Nutraceutical International Corp. (NUTR) and Schiff Nutrition International, Inc. (WNI). Neutra's Pure Plus Weight Loss supplement combines natural ingredients with Bio-Energy infusion to deliver an all-natural supplement. Bio-Energy infusion is a proprietary process that infuses specific patterns of pure "Bio-Energy" (Chi Energy or Quantum Energy) onto substances to create a unique and effective delivery system for focusing and directing the body's internal energy to different body systems or organs.
The Company is working to produce innovative, all-natural detoxification supplements to rid the body of harmful elements with no side effects. Neutra's products will include advanced and first time cleanses, organic bowel cleanses, and natural liver detox programs designed to aid the body's natural detoxification processes. Neutra is also working to produce natural sleep aids that work in harmony with the body's own chemical balance. In addition, the Company is concentrating on the production of natural energy supplements that help support high energy levels throughout the day without the side effects.
Earlier this month, Neutra announced that Chief Executive Officer Cindy Morrissey would serve as Company President following the departure of Michael-Shane Henderson, who plans to pursue other opportunities. Morrissey announced this month an expanded vision for the Company that includes the exploration of innovative new products that promote public health.
Today, Neutra announced that they signed an option agreement this week with Purlife Distributors, Inc. Purlife is the exclusive Canadian distributor of a patent-pending water-based solution known as PurTeq. This water-based solution forms an invisible, long-lasting coating that actively protects surfaces from the build up of bacteria, molds, germs and allergens.
Neutra Corp. (NTRR), closed Tuesday's trading session at $0.75, up 649.25%, on 6,997 volume with 8 trades. The average volume for the last 60 days is 216 and the stock's 52-week low/high is $0.555/$1.00.
One World Holdings, Inc. (OWOO)
Today we are reporting on One World Holdings, Inc. (OWOO), here at the QualityStocks Daily Newsletter.
One World Holdings, Inc. is the parent company of The One World Doll Project, Inc. The One World Doll Project has developed a line of multi-cultural and fashion dolls. The Prettie Girls! OWP doll line is unique in the way they look, their backgrounds and their stories. The One World Doll Project's core mission is to make one of the most significant, positive cultural impacts on play - and in the doll category - in recent history. One World Holdings lists on the OTC Market's OTCQB. The Company is based in Houston, Texas.
Last week, One World Holdings announced that they completed the process of taking the Company public and that FINRA designated their stock symbol as "OWOO." Before acquiring their stock symbol, the Company had filed a Registration Statement with the SEC, which had gone effective on December 19, 2012.
Joanne Melton, Chief Executive Officer, stated, "We are excited about becoming a public company because this represents a major milestone in setting the stage for One World to be a real competitor in the doll and toy arena. This move will also provide liquidity for our shareholders and facilitate future capital formation and growth.
She added, "As a public company we expect to make big steps forward in 2013 as we introduce The Prettie Girls! OWP, our unique multi-cultural doll line, to a market that we believe has been waiting for high quality dolls to represent true racial and ethnic diversity."
Stacey McBride-Irby designed and created numerous fashions and concepts for the Barbie® line in her 15 years at Mattel™. She created an entire new line for the company, the So In Style™ dolls, the first African-American Barbie dolls by Mattel that, according to Stacey, "more closely represented contemporary girls and young women in the diverse and dynamic urban community".
Stacey McBride-Irby is now using her love of doll making and design to create dolls with The One World Doll Project. The overall vision of One World Holdings is to introduce a new way mainstream dolls are designed, marketed and integrated into the fabric of America.
One World Holdings, Inc. (OWOO), closed Tuesday's trading session at $0.15, even for the day, on 1,520 volume with 3 trades. The average volume for the last 60 days is 571 and the stock's 52-week low/high is $0.15/$0.25.
Quantum Rare Earth Developments Corp. (QREDF)
We are highlighting Quantum Rare Earth Developments Corp. (QREDF), here at the QualityStocks Daily Newsletter.
Quantum Rare Earth Developments Corp. is an exploration stage company with headquarters in Vancouver, British Columbia. The Company formerly went by the name Butler Resource Corp. They changed their name to Quantum Rare Earth Developments Corp. in March of 2010. Quantum Rare Earth's shares trade on the OTCQX International.
The Company engages in the acquisition and exploration of mineral resource properties. Quantum is developing their 100 percent owned Elk Creek Carbonatite project in Nebraska. This is the only primary niobium deposit known to be under development in the U.S, and the highest grade undeveloped niobium deposit in North America.
Niobium is primarily used in the form of Ferro-Niobium to produce HSLA (High Strength, Low Alloy) steel, to produce lighter, stronger steel for use in automotive, structural and pipeline industries. The United States imports 100 percent of their niobium needs. Niobium is listed as a strategic metal; it is under consideration for national stockpiling in the U.S., China, and a number of European countries.
Quantum acquired the Elk Creek project in South East Nebraska on May 4, 2010. The Elk Creek project is a former Molycorp project. The Elk Creek Carbonatite is located in southeastern Nebraska an hour south of Lincoln. The niobium deposit is approximately 800 x 400 x 400 meters. The deposit is open in 3 directions including at depth.
On April 2, 2012 the Company received an updated resource estimate for the Elk Creek Niobium Deposit including the addition of higher grade indicated status tonnage of 19.3 Mt grading 0.67 percent Nb2O5. It also included an increase in inferred status tonnage and grade from the previous resource estimate (News Release dated April 28, 2011); from 80.1 Mt grading 0.62 percent Nb2O5 to 83.3 Mt grading 0.63 percent Nb2O5.
In July 2012, Quantum announced that they finalized the previously announced option of the Company's Australian Jungle Well and Laverton properties (the Australian Properties). Under the terms of an option agreement dated September 19, 2011 (Florella Option Agreement), the Company granted Florella Holdings Pty Ltd. the right to earn an 80 percent interest in the Australian Properties, upon completion of payment of cash and the issuance of shares to Quantum.
Florella assigned a portion of their interest to an unrelated third party, Victory Mines Ltd., an Australian company. Victory is headquartered in Perth, Australia. Quantum and their Australian subsidiary Northeast Minerals Pty Ltd. entered into a comprehensive Joint Venture Agreement and a Tenement Sale Agreement with Victory, their subsidiary Victory Exploration Pty. Ltd., and Florella regarding the Joint Venture of the Australian Properties.
Quantum Rare Earth Developments Corp. (QREDF), closed Tuesday's trading session at $0.11, down 8.33%, on 75,600 volume with 19 trades. The average volume for the last 60 days is 28,411 and the stock's 52-week low/high is $0.089/$0.30.
Viscount Systems, Inc. (VSYS)
The QualityStocks Daily Newsletter would like to spotlight Viscount Systems, Inc. (VSYS). Today, Viscount Systems, Inc. closed trading at $0.115, up 15.00%, on 128,881 volume with 14 trades. The stock’s average daily volume over the past 60 days is 62,701, and its 52-week low/high is $0.0069/$0.13.
Viscount Systems, Inc. was happy to report another installation order today for their advanced IT-based physical security solutions, as a sizeable complex including four high-rise towers (and ancillary commercial, retail, and underground parking areas) in Vancouver are to be fitted with the company's Freedom Access Control systems, including MESH Touch Screens, and full video capability in a contract valued at nearly $200k. CEO of VSYS, Stephen Pineau, emphasized how this project clearly highlights one big advantage of the Freedom Access Control system for retrofits, modularity, and hardware agnosticism, something which makes VSYS vastly preferable to the typical proprietary hassle of existing competitors.
Viscount Systems, Inc. (VSYS) designs, manufactures, and services access control and security products such as door access control systems and emergency communications systems. The company's products have been installed in approximately 35,000 sites in over 30 countries, including prisons, schools, hospitals, and corporate offices.
Designing security systems since 1969, the company has developed strategic working relationships with leading equipment vendors to support its continued profitability and growth. Viscount has been consistently profitable for nearly 15 years and currently generates annual revenues of approximately $5 million.
Five hundred dealers help distribute Viscount's existing products throughout North America. This distribution network is not static as the company constantly pursues additional sales channels. Products are advertised in various print publications and regularly displayed at tradeshows as well. Direct marketing via training seminars also helps drive sales.
Viscount's management team has more than 60 years of combined experience in the development and production of electronic door control and telecommunication systems. Under this leadership, the SIA Convergence Solution of the Year accolade and Platinum Award for Emergency Response and Gold Award for Access Control at the Government Security Awards (GOVSEC) for 2011 have been presented to the company. Disclaimer
Viscount Systems, Inc. Company Blog
Viscount Systems, Inc. News:
Viscount Systems Receives Contract to Secure Four High Rise Towers
Viscount Systems Awarded Contract to Secure North Dakota Schools
Viscount Systems Receives Microsoft “Be What’s Next” Award
Cardium Therapeutics, Inc. (CXM)
The QualityStocks Daily Newsletter would like to spotlight Cardium Therapeutics, Inc. (CXM). Today, Cardium Therapeutics, Inc. closed trading at $0.19, up 5.50%, on 278,319 volume with 139 trades. The stock’s average daily volume over the past 60 days is 200,491, and its 52-week low/high is $0.17/$0.399.
Cardium Therapeutics, Inc. announced they offered an insightful look at the company's rapidly evolving Generx® platform, as company CSO, Gabor M. Rubanyi, M.D., Ph.D., detailed the latest knowledge about the underlying mechanics of therapeutic angiogenesis in a presentation that was delivered at the 2013 Phacilitate Annual Cell & Gene Therapy Forum in Washington, DC. Generx is an interventional cardiology-focused product designed for one-time, non-surgical treatment of CMI (cardiac microvascular insufficiency) in patients with coronary artery disease conditions, and Dr. Rubanyi covered the company's clinical development program for Generx in the presentation (currently available online at www.cardiumthx.com/generx.html).
Cardium Therapeutics, Inc. (CXM) is a health sciences and regenerative medicine company focused on acquiring and strategically developing new and innovative products and businesses to address significant unmet medical needs. Comprised of large-market opportunities with definable pathways to commercialization, partnering, and other economic monetizations, Cardium's current portfolio includes the Tissue Repair Company, Cardium Biologics, and the company's in-house MedPodium Health Sciences healthy lifestyle product platform.
The company's lead commercial product Excellagen® topical gel for wound care management recently received FDA clearance for marketing and sale in the United States. In addition to plans to advance the product's commercialization in the U.S. and internationally via strategic partnerships, the company plans to develop new product extensions for additional wound healing applications and is working towards securing approval for marketing and sale in South Korea and through the CE Mark application process in the European Union.
Generx®, Cardium's lead clinical development product candidate, is a DNA-based angiogenic biologic designed to treat patients with myocardial ischemia due to coronary artery disease. Cardium recently initiated its Generx Phase 3 / registration study in Russia. Consistent with its capital-efficient business model, Cardium is also actively evaluating new technologies and business opportunities. The company utilizes its team's skills in late-stage product development to bridge the critical gap between promising new technologies and product opportunities that are ready for commercialization.
Cardium is dedicated to building on its core products and product candidates to continually create new opportunities for greater success. Leveraging the advantages of its capital-efficient, asset-based business strategy, the company provides a diversified and more balanced portfolio of risk/return opportunities with the chief objective of providing long-term shareholder value. Disclaimer
Cardium Therapeutics, Inc. Company Blog
Cardium Therapeutics, Inc. News:
Cardium Announces Presentation at The 2013 Cell & Gene Therapy Forum
Cardium To Present At Biotech Showcase 2013 Investment Conference And Report On New Cardium Initiatives
Cardium Announces Sales and Distribution Agreement With Academy Medical to Promote Excellagen Clinical Adoption by U.S. Government Medical Providers
International Stem Cell Corp. (ISCO)
The QualityStocks Daily Newsletter would like to spotlight International Stem Cell Corp. (ISCO). Today, International Stem Cell Corp. closed trading at $0.35, up 27.27%, on 867,870 volume with 208 trades. The stock’s average daily volume over the past 60 days is 158,749, and its 52-week low/high is $0.161/$0.65.
International Stem Cell Corp. (ISCO) specializes in the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. The company was first to perfect the natural phenomenon of parthenogenesis, which utilizes unfertilized human eggs to create hpSCs. These stem cells, created in a particular form called HLA homozygous, can be immune-matched to millions of people regardless of sex or racial background, with minimal expectation of immune rejection after transplantation.
hpSCs are as pluripotent as embryonic stem cells (ESCs) and have significant therapeutic potential but their creation does not involve the destruction of a viable human embryo – thus sidestepping the controversy and ethical dilemmas associated with the use of human embryonic stem cells. Different from induced pluripotent stem cells (iPSs), hpSCs do not involve manipulation of gene expression back to a less differentiated stage – a practice that may become a safety or regulatory obstacle in clinical applications.
A relatively small number of hpSC lines can offer the potential of producing the first true stem cell bank, UniStemCell, which ISCO intends to create as a means of serving populations across the globe. The company's scientists are currently focused on using hpSC to treat severe diseases of the eye, nervous system, and liver, for which cell therapy has been clinically proven but is limited due to the unavailability of safe human cells.
In addition to its therapeutic focus, ISCO also provides two revenue streams. Firstly through its subsidiary Lifeline Cell Technology, specialized cells and growth media for biological research around the world, and secondly its subsidiary Lifeline Skin Care, the company manufactures and sells anti-aging skincare products utilizing an extract from the hpSC and by leveraging the latest discoveries in the fields of stem cell biology, nanotechnology, and skin cream formulation technology. Disclaimer
International Stem Cell Corp. Company Blog
International Stem Cell Corp. News:
International Stem Cell Corporation Announces Positive Animal Efficacy Results in Liver Disease Program
International Stem Cell Corporation to Participate in Biotech Showcase 2013 on January 7th
Lifeline Skin Care a Subsidiary of ISCO Announces New Sales and Multi-Media Marketing Campaigns
TNI BioTech, Inc. (TNIB)
The QualityStocks Daily Newsletter would like to spotlight TNI BioTech, Inc. (TNIB). Today, TNI BioTech, Inc. closed trading at $7.25, up 0.69%, on 13,763 volume with 37 trades. The stock’s average daily volume over the past 60 days is 27,825, and its 52-week low/high is $0.72/$10.37.
TNI BioTech, Inc. (TNIB) is focused on utilizing patented immunotherapy to activate and mobilize the body's immune system to combat fatal diseases. The company's products and technologies improve the treatment and diagnosis of cancer, infections such as HIV/AIDS, and autoimmune diseases. Future initiatives include treatment for multiple sclerosis, herpes viral infections, and other conditions that result in altered-immune response.
The company's product portfolio currently includes IRT-101, an active immunotherapy that works by activating a patient's immune system against infectious diseases and tumor cells; IRT-102, an adaptive immunotherapy that works by isolating and enriching a patient's own immune cells; and IRT-103, an active immunotherapy that works by activating a patient's immune system against HIV/AIDS and tumor cells.
Leveraging the advantages of today's cutting-edge treatment options, the company aims to meet the growing demand for quality healthcare with safer, more effective radiation therapy; new-targeted drug therapies; and minimally invasive surgical alternatives around the world. TNI BioTech most recently signed a letter of intent to open clinics in Africa that will provide advanced treatment for cancer, HIV/AIDS, and autoimmune diseases.
The company plans to continue clinical trials in China during 2012 and 2013, and anticipates starting trials in the United States by early 2013.The company is also in negotiations to acquire a number of other immunotherapy products, patents, and therapies. Led by a management team with decades of experience and solid business plan, TNI BioTech is poised to improve healthcare with active and adaptive forms of improved immunotherapies. Disclaimer
TNI BioTech, Inc. Company Blog
TNI BioTech, Inc. News:
TNI BioTech, Inc. Announces Appointment of New CFO
TNI BioTech, Inc. Acquires the Exclusive Rights to Low Dose Naltrexone and Other Opioid Antagonists for the Treatment of Inflammatory and Ulcerative Diseases of the Bowel
TNI BioTech to Present at 6th Annual OneMedForum San Francisco 2013
Viscount Systems, a leading-edge supplier of security systems and software, announced this morning that it will be retrofitting a mixed-use complex in Vancouver with MESH Touch Screens, Freedom Access Control, and video. The area to be secured includes four high-rise towers, commercial and retail areas, as well as underground parking. The value of the contract has been reported at just under $200,000.
“This project highlights a primary advantage of our Freedom access control technology for retrofit projects,” stated Stephen Pineau, CEO of Viscount. “Because most existing systems are highly proprietary, retrofitting a security system normally requires the replacement of every system component including access cards and the card readers at each door. However, Freedom is a software platform than can read the card of almost every existing supplier. By allowing the client to make use of their existing cards and door readers we were able to provide a significant cost advantage before any other component was even included.”
Designing security systems since 1969, Viscount has developed strategic working relationships with leading equipment vendors to support its continued profitability and growth. The company’s products have been installed in approximately 35,000 sites in over 30 countries, including prisons, schools, hospitals, government facilities, and corporate offices.
For more information on Viscount Systems, visit www.viscount.com
Today before the opening bell, Cardium Therapeutics announced its Chief Scientific Officer, Gabor M. Rubanyi, M.D., Ph.D. delivered a presentation at the 2013 Phacilitate Annual Cell & Gene Therapy Forum in Washington, DC. The presentation, titled “Optimizing Phase III Trial Design for Generx® (Ad5FGF-4),” outlined the current scientific knowledge about the mechanistic basis of adaptive coronary collateral growth, the biological processes to be targeted by therapeutic angiogenesis, and the lessons learned during the past decade of the company’s Generx clinical development program.
If you would like to view the presentation, visit http://www.cardiumthx.com/generx.html.
“The presentation yesterday reviewed new techniques that have been implemented to optimize our international Phase 3 ASPIRE clinical study for the Company’s Generx® (Ad5FGF-4) DNA-based angiogenic growth factor drug candidate, including: (1) diagnostic identification of patients likely to be more responsive to angiogenic therapy; (2) new balloon catheter-based delivery methods designed to boost adenovector gene delivery and enhance angiogenic growth factor efficiency; and (3) selection of relevant clinical endpoints which may be useful in future clinical studies and help advance the field of therapeutic angiogenesis,” stated Christopher J. Reinhard, Cardium’s Chairman and CEO.
Generx is an interventional cardiology-focused product candidate that is being developed to offer a one-time, non-surgical option for the treatment of a medical condition termed cardiac microvascular insufficiency (CMI) in patients with myocardial ischemia and symptomatic chronic stable angina pectoris due to coronary artery disease. Patients with CMI have had an insufficient angiogenic response to their current disease state and may benefit from a biological therapy that enhances cardiac perfusion through the facilitation of collateral vessel formation. Currently, patient inclusion in the ASPIRE study requires evidence of stress induced reversible myocardial ischemia as measured by SPECT imaging. The goal of the company’s Generx product candidate is to improve blood flow to the heart muscle by promoting and enhancing cardiac perfusion through the enlargement of pre-existing collateral arterioles (arteriogenesis) and the formation of new capillary vessels (angiogenesis). Various catheter-based imaging diagnostics including fractional flow reserve and washout collaterometry could enhance the clinical adoption of this non-surgical therapeutic angiogenesis approach following initial registration.
Cardium’s extensive preclinical and clinical studies have been instrumental in identifying cardiac ischemia as a key facilitator of non-surgical DNA-based angiogenic therapy. Improved adenovector administration methods combine non-surgical, percutaneous balloon catheter-based delivery to transiently induce ischemia together with the use of nitroglycerin to enhance vector uptake. By increasing cell transfection efficiency and reaching both the peri-ischemic regions and pre-existing collaterals in the heart, this modified approach offers the potential to effectively simulate both angiogenesis and arteriogenesis to bring about improved blood flow. Cardium’s new delivery techniques are also designed to provide uniform Generx uptake, to reduce response variability and to allow for the potential treatment of patients with a broader range of associated coronary artery disease.
Cardium has modified the primary endpoint of the ASPIRE clinical study from the traditional measure of improvement in treadmill exercise time (ETT) to a more objective efficacy endpoint of reduction in reversible perfusion deficit based on SPECT myocardial perfusion imaging. Similar to mechanical/surgical cardiac revascularization approaches, the goal of Generx treatment is to improve myocardial perfusion (blood flow). SPECT myocardial perfusion imaging can be used to quantitatively evaluate Generx’s effectiveness by measuring improved myocardial blood flow under stress, a key prognostic indicator that is associated with the regenerative process of new collateral vessel formation in and around the regions of ischemia. While walking time during ETT has been a traditional efficacy measure of anti-anginal drugs, it is based on a subjective assessment of chest pain (angina pectoris), does not directly measure improvements in cardiac blood flow, and can be affected by other variables.
Positive results from the prior Phase 2a clinical study (Grines et al., J Am Coll Cardiol 2003; 42:1339-47) showed that Generx improved myocardial blood flow in the ischemic region of the hearts of patients following a single intracoronary infusion as measured by the objective efficacy endpoint of SPECT imaging. The observed treatment effect for patients receiving Generx was similar in magnitude to that reported in the literature for patients undergoing angioplasty/stent or revascularization procedures with reversible perfusion defects of comparable size at one year following these procedures.
For more information, visit www.CardiumTHX.com
The Lifeline Cell Technology subsidiary of International Stem Cell Corp. specializes in the development and manufacture of purified primary human cells and optimized reagents for cell culture. The company’s scientists continue to come up with new and improved human cell systems for the worldwide culture marketplace and are making breakthroughs in the development of human stem cell production. Their strength rests in both the established quality and range of their products, which are listed below.
• Smooth muscle
• Stem cells, human
• Stem cells, non-human
• Blood Immune System
• Endothelial-Large Vessel
• Endothelial-Small Vessel
• Smooth muscle
• Stem cells, human
Cell Culture Media:
• Blood Immune System
• Endothelial-Large Vessel
• Endothelial-Small Vessel
• Smooth muscle
• Stem cells, human
• Reagents, supplements and growth factors
• Skin models
• Stem Cell Differentiation Kits
For additional information, visit www.InternationalStemCell.com and www.LifelineSkinCare.com
Richfield Oil & Gas today joins the cream of the crop on OTC Markets Group’s premier platform, the OTCQX®, where timely financial and reporting standards have skimmed off high-quality U.S. companies such as this Utah-based hydrocarbon developer, which has an extensive footprint of producing oil and gas assets in Kansas and Wyoming, as well as ancillary development assets in Oklahoma and Utah. OTCQX brings quality-control and a level of marketplace services formerly only available to companies and their investors via a traditional U.S. exchange.
OTCQX is a great venue for drawing interest and represents the highest financial standards and third-party sponsorship in the OTC space. This move is a firm commitment by Richfield to doubling-down on U.S. investor engagement metrics and is wholly in line with an established practice of maintaining consistent, superior-quality data and reporting, such that markets are able to make intelligent decisions on the company’s securities.
CEO of ROIL, Douglas C. Hewitt, Sr., affirmed the company’s dedication to ensuring that investors are able to do comprehensive analysis and be totally confident in the fact that they have a circumspect valuation, emphasizing how important it is to management that investors are able to make the best trades possible when it comes to ROIL. Hewitt conveyed a strong sense of understanding about how timely, accurate news and top-shelf data is the cement which bonds together company/shareholder relationships.
President and CEO of OTC Markets Group, R. Cromwell Coulson, stressed how crucial the philosophy of open, transparent, and connected financial marketplaces was in today’s environment, welcoming ROIL’s move to the top-tier of the OTC space. Coulson detailed how OTCQX is a prime way to show investors that the company is a cut above other OTC listings, adding that with a fully electronic marketplace which is also compliance-driven, you have a nexus of easy access and consistent reportage.
A solid dynamics move for ROIL to throw a spotlight on their growing portfolio of domestic hydrocarbon interests, having recently (Jan 9) snapped up a 100% WI in a 640-acre producing (Wasatch National Forest Well #16-15) mineral lease in the Graham Reservoir oil field, Uinta County, Wyoming.
For more information on Richfield Oil & Gas Company, please visit www.RichfieldOilAndGas.com
Today's Top 3
The QualityStocks Public Company Sponsor News